Risk of liver disease in HCV-seropositive kidney transplant recipients.
OBJECTIVE
This study determined whether renal allograft recipients with antibodies to hepatitis C virus (HCV) at the time of transplantation experienced increased morbidity or mortality from hepatitis, liver disease, or hepatocellular carcinoma compared with patients without anti-HCV.


BACKGROUND
Chronic liver disease is a cause of significant morbidity and mortality after kidney transplantation and the contribution of HCV to this problem has not been determined. The recent characterization of the HCV genome has resulted in the development of screening tests for antibody to HCV, allowing the identification of end-stage renal disease patients with anti-HCV who are candidates for transplantation. The risk to these patients for the development of hepatic complications after subsequent transplantation is unknown.


METHODS
Archived sera obtained from 163 kidney transplant recipients at the time of transplantation were tested for anti-HCV using the Abbott HCV 2.0 second-generation test system. Sera containing anti-HCV were further analyzed for reactivity against specific HCV recombinant proteins, including core, NS3 (c33c), and NS4 (c100-3), to determine whether a pattern could be identified in patients with hepatic complications. The follow-up of all patients was current (mean length of follow-up was 33 months) to identify patients with hepatic complications. All patients had previously been tested for HBSAg.


RESULTS
Twenty-nine patients (18%) had anti-HCV and three (1.8%) had HBSAg. Forty-five patients (28% of total) had transient elevations of AST or ALT without subsequent evidence of liver disease. Three patients had a syndrome of acute hepatitis. Chronic liver disease developed in only six patients (3.6%) after transplantation. Four had anti-HCV only, one had HBSAg only, and one was positive for both. However, of the 29 patients with anti-HCV, chronic liver disease developed in 5 (17%), including 1 patient who was positive for HBSAg. No patient had hepatocellular carcinoma.


CONCLUSIONS
Perturbations of liver function were common in the kidney transplant recipients studied, most were self-limited, and few were associated with evidence of viral hepatitis. The risk of developing
Rohr
M S
MS
Bowman Gray School of Medicine, Winston-Salem, North Carolina.
Lesniewski
R R
RR
Rubin
C A
CA
Johnson
R G
RG
Heise
E R
ER
McDonald
J C
JC
Adams
P L
PL
D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D002908:Chronic Disease; D005500:Follow-Up Studies; D016174:Hepacivirus / Q000276:immunology*; D006508:Hepatitis Antibodies / Q000097:blood*; D006514:Hepatitis B Surface Antigens / Q000097:blood; D006801:Humans; D016030:Kidney Transplantation; D008107:Liver Diseases / Q000209:etiology* / Q000276:immunology; D017093:Liver Failure / Q000276:immunology; D008875:Middle Aged; D011183:Postoperative Complications / Q000209:etiology* / Q000276:immunology; D012307:Risk Factors
D006508:Hepatitis Antibodies; D006514:Hepatitis B Surface Antigens